It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Shionogi Launches New Manufacturing Subsidiary, Commencing Operations in April Next Year
October 18, 2018
- Eisai’s Insomnia Treatment Lemborexant Smashes Primary Target in Long-Term PIII Study
October 18, 2018
- Daiichi Sankyo Files Quizartinib for AML in Japan
October 18, 2018
- JAK Inhibitor Battle for Atopic Dermatitis Intensifying, 1st Japan Filing Might Be Near
October 17, 2018
- Eisai Seals Latin America Pact for Belviq
October 17, 2018
- Teva Takeda Launches Voluntary Recall for Taxotere Generics
October 17, 2018
- Chugai’s Satralizumab Cuts Relapse Risk of Neuromyelitis Optica Spectrum Disorder
October 16, 2018
- Ono Joins GHIT Fund as 21st Funding Partner
October 16, 2018
- China Regulators Accept NDA for Fycompa
October 15, 2018
- Chugai Sues Daiichi Sankyo, Pfizer over Herceptin Biosimilars
October 15, 2018
- Oncodesign Strengthens Its Cooperation with Eisai
October 15, 2018
- Kyorin Begins Collaborative Research on Antibiotics with Microbial Chemistry Research Foundation
October 12, 2018
- Nippon Shinyaku to Expand Contract Manufacturing Biz with New Facility to Start Full Operation in Feb.
October 12, 2018
- Avastin Top-Seller in Japan for 2nd Straight Month in September: Encise Snapshot
October 11, 2018
- Perjeta Gets Japan OK as Neoadjuvant, Adjuvant Therapy for HER2 Breast Cancer
October 11, 2018
- Shonan iPark to Focus on Disease Prevention, 3 Other Areas, Aiming to House 200 Companies by FY2023
October 11, 2018
- Towa’s Allegra Generic Grabs Approval for Expanded Pediatric Use
October 11, 2018
- Opdivo/Yervoy Combo Gets 1st Line RCC Nod in South Korea
October 10, 2018
- Ethical Drug Sales Down 2.0% in August: Crecon
October 10, 2018
- Celgene’s CAR-T Therapy Earns Orphan Status in Japan
October 10, 2018
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…